Syndax Pharmaceuticals Is Down 51% Even Though Sales Rose

Syndax Pharmaceuticals has had a packed 2026, from strong Q1 and Q2 updates on Revuforj and Niktimvo to an abrupt share-price hit after axatilimab failed its Phase 2 IPF trial. Investors who held Syndax Pharmaceuticals from the start of the year are down 50.9%, including dividends. If you had made that call on 1 January, how should the blend of early optimism and later setbacks change what you now expect from its concentrated oncology portfolio?

Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.

The move put Syndax Pharmaceuticals in the middle of this trade. Scan 38 healthcare AI stocks for other companies exposed to it.

The Argument You Would Have Been Weighing Up On Syndax Pharmaceuticals

The shares cost US$21.01 at the start of the period, and Syndax Pharmaceuticals sat between two sharply different stories.

The bullish narrative put Fair Value at US$36.55, built on revenue growth assumptions of 97.8% and a move from a very large loss margin to 7.2% in three years, driven by broader Revuforj and Niktimvo usage.

The bearish view set Fair Value at US$19 and leaned on a profit margin assumption of 16.3% and a 27.9x future P/E. It also stressed the risk that heavy reliance on two drugs and pricing pressure could cap progress.

What The Evidence Did To The Syndax Pharmaceuticals Argument

The big swing factor was axatilimab’s failed Phase 2 IPF trial, which directly challenged the bullish case that treated Niktimvo’s label expansions as a core growth driver. Strong Q1 and Q2 updates on Revuforj and Niktimvo, together with Q3 2026 revenue of US$83.3 million and a less negative net margin of 59.3%, supported the more cautious story. Profit remains in loss territory, so the profitability promise is still unproven.

The lesson is simple. When you see a forecast built on one or two drugs, test it against later trial outcomes and the net margin trend, not just headline revenue.

What You Would Be Paying For In Syndax Pharmaceuticals Today

Syndax Pharmaceuticals now trades at US$10.45, and the selected Narrative’s Fair Value sits above that price. The argument focuses on Revuforj and Niktimvo potentially developing into larger oncology franchises while the broader pipeline gradually widens potential earnings power.

The question for you is whether the current drop only reflects short term IPF disappointment. A buyer today would need to believe that commercial momentum in Revuforj and Niktimvo holds up while fixed operating costs remain contained.

"The current valuation implies the market is still discounting the scale of Revuforj and Niktimvo cash flows and gives limited credit to the pipeline. This is consistent with a view that Syndax Pharmaceuticals is undervalued."

One Narrative disagrees with today's price. → See where this Narrative says Syndax Pharmaceuticals should trade

Another Way To Read Syndax

Syndax Pharmaceuticals leaves you thinking about one thing. Who else is fighting the same oncology and immunology battles from a different angle?

Here, one giant drug maker is rebuilding around non pandemic treatments. It is leaning into obesity medicine and cancer drugs that link targeted antibodies with toxic payloads.

Those efforts are meant to replace fading cash flows and reshape its earnings mix. The same push puts fresh attention on how efficiently research spending turns into durable therapies.

If you are testing Syndax against peers, that shift matters. It hints at how a large rival is trying to balance cost cuts, trial risk and a crowded drug pipeline.

It is written up in full, assumptions and all. → Explore the Narrative that puts this company 17% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com